|
|
Agendia News and Press Releases
For all media and investor relations inquiries, please contact:
Hans Herklots
Head of Corporate Communications
Telephone: +31 20 462 1557
Email: hans.herklots@agendia.com
|
Sort by Date
|
Sort by Article
|
|
08/05/10
|
Agendia inaugurates new state-of-the-art clinical genomics laboratory in Irvine, CA.
Agendia today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia’s offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia’s strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research.
|
|
07/15/10
|
Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
Agendia announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs). The FDA has decided that LDTs which have not been properly validated put patients at risk, and that a risk-based application of oversight for the category is appropriate. Agendia joins the FDA among other leading organizations in calling for a tiered risk-based approach to the regulation of LDTs.
|
|
06/04/10
|
Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
Researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia’s MammaPrint®, BluePrint™, and ColoPrint™ at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. The study results underpin the broad predictive and prognostic power of MammaPrint and highlight prospective and independently validated data on ColoPrint. Visitors can meet the Agendia team in booth #18018.
|
|
04/29/10
|
New Study Demonstrates Patients with High-Risk MammaPrint Profile Benefit from Chemotherapy
At the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test.
|
|
03/24/10
|
Agendia Launches BluePrint™ Expanding Breast Cancer Product Offering
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, March 24, 2010 – Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint®, and TargetPrint™, has been expanded with BluePrint ™ to report important additional information on tumor subtypes.
|
|
